Intestinal drug efflux: Formulation and food effects

Advanced Drug Delivery Reviews

Volumn 50, Issue SUPPL. 1, 2001, Pages

  Wagner, D ^a   Spahn Langguth, H ^b   Hanafy, A ^b   Koggel, A ^a   Langguth, P ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Efflux pump; Intestinal perfusion; Intestinal permeability; Intestinal secretion; Multidrug resistance protein family; P Glycoprotein; Site dependent absorption

Indexed keywords

ABSORPTION; BIOLOGICAL ORGANS; CELLS; METABOLISM; MONOLAYERS; POLYPEPTIDES; PROTEINS;

SECRETORY TRANSPORTERS;

DRUG DOSAGE;

ACETONITRILE; ALCOHOL; ALDOSTERONE; ALPHA TOCOPHEROL; CIMETIDINE; CREMOPHOR; CYCLOSPORIN A; DAUNORUBICIN; DEXAMETHASONE; DIGOXIN; DIMETHYL SULFOXIDE; DRUG CARRIER; ETOPOSIDE; EXCIPIENT; GLYCOPROTEIN P; HYDROCORTISONE; KETOCONAZOLE; MACROGOL 400; N,N DIMETHYLACETAMIDE; PACLITAXEL; POLOXAMER; POLYSORBATE 80; PROPYLENE GLYCOL; RANITIDINE; RHODAMINE 123; SALBUTAMOL; TALINOLOL; TRITON X 100; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; VINBLASTINE SULFATE; VINCRISTINE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; CELL STRAIN CACO 2; COLON ABSORPTION; COLON SECRETION; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG POTENCY; DRUG STABILITY; DRUG TRANSPORT; FRUIT JUICE; HUMAN; HUMAN CELL; INTESTINE PERFUSION; INTESTINE SECRETION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMALL INTESTINE ABSORPTION;

ANIMALS; DRUG CARRIERS; FOOD-DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; INTESTINES; PHARMACEUTICAL PREPARATIONS; RATS;

EID: 0035478718     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(01)00183-1     Document Type: Conference Paper

References (87)

1. Charles Ernest Overton's concept of a cell membrane
2. Carrier-mediated intestinal transport of drugs
3. Resorption und sekretion von arzneistoffen durch die mukosaepithelien des gastrointestinaltraktes
4. Drug transport in intestine, liver and kidney
5. Drug exsorption from blood into the gastrointestinal tract
6. Modulation of multidrug resistance: A paradigm for translational clinical research
7. Antibiotic efflux pumps
8. Structure-activity relationship of P-glycoprotein substrates and modifiers
9. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: A comparison
10. The biology of the P-glycoproteins
11. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
12. Structure and expression of the human MDR (P-glycoprotein) gene family
13. Both ATP sites of human P-glycoprotein are essential but not symmetric
14. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporine A
15. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
16. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: Drugs and analogs, stereoisomers and metabolites
17. The multidrug resistance protein family
18. Efflux of dietary flavonoid quercetin 4′-β-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2
19. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions
20. Biliary excretion of pravastatin in rats: Contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter (cMOAT)
21. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier
22. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines
23. r 190 000 multidrug resistance protein (MRP): Evidence for cotransport with reduced glutathione
24. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1
25. Organic cation transporters in intestine, kidney, liver and brain
26. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter
27. Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1
28. A reevaluation of substrate specificity of the rat cation transporter rOCT1
29. Renal secretion of organic cations: A multistep process
30. β-Lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter
31. The secretory intestinal transport of some β-lactam antibiotics and anionic compounds: A mechanism contributing to poor oral absorption
32. Calcein is excreted from the intestinal mucosal cell membrane by the active transport system
33. Net secretion of furosemide is subject to indomethacin inhibition, as observed in Caco-2 monolayers and excised rat jejunum
34. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family
35. Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA (hPGT)
36. Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations
37. Possible role of anion exchanger AE2 as the intestinal monocarboxylic acid/anion antiporter
38. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines
39. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance
40. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine
41. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine
42. Atorvastatin transport in the Caco-2 cell model: Contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter
43. Bisubstrates: Substances that interact with both, renal contraluminal organic anion and organic cation transport systems II
44. P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound
45. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach
46. Unexpected effect of verapamil on oral bioavailability of the β-blocker talinolol in humans
47. Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms
48. Segmental differences in drug permeability, esterase activity and ketone reductase activity in the albino rabbit intestine
49. Membrane transport of drugs in different regions of the intestinal tract of the rat
50. Non-ionic detergent Tween 80 modulates VP-16 resistance in classical multidrug resistant K562 cells via enhancement of VP-16 influx
51. Fundamental relationships between block copolymers and their hypersensitization effect in MDR cancer cells
52. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers
53. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo
54. Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models
55. Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs
56. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system
57. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells
58. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers
59. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: Permeabilities via diffusion, inside- and outside-directed carrier-mediated transport
60. Structure-permeation relations of Met-enkephalin peptide analogues on absorption and secretion mechanisms in Caco-2 monolayers
61. Intestinal absorption of the quaternary trospium chloride: Permeability-lowering factors and bioavailabilities for oral dosage forms
62. Compound mixtures in Caco-2 cell permeability screens as a means to increase screening capacity
63. Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats
64. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol
65. The effects of lipids and detergents on ATPase-active P-glycoprotein
66. Effects of detergents on P-glycoprotein ATPase activity: Differences in pertubations of basal and verapamil-dependent activities
67. Reversal of multidrug resistance phenotype by surfactants: Relationship to membrane lipid fluidity
68. Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein
69. The contribution of P-glycoprotein to pharmacokinetic drug/drug interactions
70. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
71. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction
72. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum)
73. Flavonol-stimulated efflux of 7,12-dimethylbez(a)anthracene in multidrug-resistant breast cancer cells
74. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast cancer cell line. P-glycoprotein as a possible target
75. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-gp
76. Acceleration of MRP-associated efflux of rhodamine 123 by genistein and related compounds
77. Grapefruit juice activates P-glycoprotein-mediated drug transport
78. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism
79. P-Glycoprotein possesses a 1,4-dihydropyridine-selective drug acceptor site which is allosterically coupled to a vinca-alkaloid-selective binding site
80. Comparison of effects of natural or artificial rodent diet on etoposide absorption in rats
81. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in Caco-2 cells
82. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice
83. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid
84. Drug-grapefruit juice interactions
85. Inhibition of P-glycoprotein by orange juice components, polymethoxyflavones in adriamycin-resistant human myelogeneous leukemia (K562/ADM) cells
86. Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4
87. 1-selektiver betablocker - Eine übersicht zu pharmakokinetischen und pharmakodynamischen eigenschaften